{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-022709","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.002970+00:00","generated_at":"2026-06-01T06:12:29.020691+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024","bullets":["Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.","Consulting agreement: €104,000 annual compensation, plus options for 15,000 shares at Nasdaq closing price on July 1, 2024, vesting quarterly over 3 years.","Schellens brings 25+ years oncology experience, former CMO at Byondis B.V., board member of Dutch Medicines Evaluation Board.","He will lead clinical trial oversight, regulatory strategy, and serve as primary medical monitor.","Agreement provides for services 2 days per week, based in Netherlands; term until terminated by either party with 60 days' notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-022709","json":"https://secwatch.observer/filing/0001493152-24-022709.json","markdown":"https://secwatch.observer/filing/0001493152-24-022709.md","text":"https://secwatch.observer/filing/0001493152-24-022709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/0001493152-24-022709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:12:29.020691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6406cec9be","claim":"Jan Schellens was appointed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..","evidence_excerpt":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/0001493152-24-022709-index.htm","confidence":0.6,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}